OncoMed Pharmaceuticals
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, OncoMed Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#626 of 15,742 sponsors by registered trial count).
OncoMed Pharmaceuticals: 25 sponsored US clinical trials, none currently recruiting.
OncoMed Pharmaceuticals sponsors 25 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 20 completed. 0 of these trials are in Phase 3-4 (later-stage) and 25 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Solid Tumors, with 2 trials.
Top-decile sponsor footprint
OncoMed Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#626 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
20 of 25 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (80.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
25 total, page 1 of 1
A Study of OMP-336B11 in Subjects With Locally Advanced or Metastatic Tumors
NCT03295942
A Study of OMP-313M32 in Subjects With Locally Advanced or Metastatic Solid Tumors
NCT03119428
A Study of Brontictuzumab With Chemotherapy for Subjects With Previously Treated Metastatic Colorectal Cancer
NCT03031691
A Phase 1b Study of OMP-305B83 Plus Paclitaxel in Subjects With Ovarian, Peritoneal or Fallopian Tube Cancer
NCT03030287
A Study of OMP-305B83 in Subjects With Metastatic Colorectal Cancer
NCT03035253
A Phase 1b Study of Demcizumab Plus Pembrolizumab in Locally Advanced or Metastatic Solid Tumors
NCT02722954
A Phase 1a/b Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of OMP-131R10
NCT02482441
Study of Gemcitabine, Abraxane® Plus Placebo Versus Gemcitabine, Abraxane® Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With 1st-Line Metastatic Pancreatic Ductal Adenocarcinoma
NCT02289898
A Study of Carboplatin, Pemetrexed Plus Placebo vs Carboplatin, Pemetrexed Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With Non-Squamous Non-Small Cell Lung Cancer
NCT02259582
A Phase 1 Study of OMP-305B83 in Subjects With Solid Tumors
NCT02298387
Dose Escalation Study of OMP-54F28 in Combination With Paclitaxel and Carboplatin in Patients With Recurrent Platinum-Sensitive Ovarian Cancer
NCT02092363
Dose Escalation Study of OMP-54F28 in Combination With Sorafenib in Patients With Hepatocellular Cancer
NCT02069145
Dose Escalation Study of OMP-54F28 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Previously Untreated Stage IV Pancreatic Cancer
NCT02050178
A Study of Vantictumab (OMP-18R5) in Combination With Docetaxel in Patients With Previously Treated NSCLC
NCT01957007
A Study of Vantictumab (OMP-18R5) in Combination With Nab-Paclitaxel and Gemcitabine in Previously Untreated Stage IV Pancreatic Cancer
NCT02005315
A Study of Vantictumab (OMP-18R5) in Combination With Paclitaxel in Locally Recurrent or Metastatic Breast Cancer
NCT01973309
A Study of Demcizumab Plus Paclitaxel in Subjects With Platinum Resistant Ovarian
NCT01952249
A Dose Escalation Study of OMP-52M51 in Subjects With Solid Tumors
NCT01778439
A Dose Escalation Study of OMP-52M51 in Subjects With Lymphoid Malignancies
NCT01703572
A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Stage IV Pancreatic Cancer
NCT01647828
A Dose Escalation Study of OMP-54F28 in Subjects With Solid Tumors
NCT01608867
A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Etoposide and Platinum Therapy
NCT01859741
A Dose Escalation Study of OMP-18R5 in Subjects With Solid Tumors
NCT01345201
A Dose Escalation Study of OMP-59R5 in Subjects With Solid Tumors
NCT01277146
A Phase 1 Dose Escalation Study of OMP-21M18 in Subjects With Solid Tumors
NCT00744562
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 23 |
| Phase 2 | 2 |
Therapeutic Areas
How the OncoMed Pharmaceuticals early-phase archive is shaped
25 indexed studies, none listed as recruiting (0% open); 20 completed (80%).
Phase mix: 0 late (III/IV) vs 25 early (I/II) (early-phase heavy).
Top condition: Solid Tumors (2 trials), 7 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
OncoMed Pharmaceuticals: archived-pipeline peers nationwide
Peers matched on 25 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
OncoMed Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 25 archived trials
- Arcus Biosciences · 25 trials · 12% recruiting
- Arcutis Biotherapeutics · 25 trials · 8% recruiting
- Ardelyx · 25 trials · 12% recruiting
- Drexel University College of Medicine · 25 trials · 0% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this OncoMed Pharmaceuticals page
25 registered trials is a research-attention snapshot, not an endorsement of OncoMed Pharmaceuticals or any single study.
- None of OncoMed Pharmaceuticals's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Solid Tumors is the condition OncoMed Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Solid Tumors trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
OncoMed Pharmaceuticals pipeline card: 25 registered trials from official public datasets.Report a data error.